Quantity of eligible individuals: CDEC discussed the uncertainty in the number of clients with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are categorized as getting mild or moderate disease can have a critical bleeding https://anneg678uts9.smblogsites.com/profile